Author:
Ganesh Shanthi,Kim Min Ju,Lee Jenny,Feng Xudong,Ule Krisjanis,Mahan Amy,Krishnan Harini Sivagurunatha,Wang Zhe,Anzahaee Maryam Yahyaee,Singhal Garima,Korboukh Ilia,Lockridge Jennifer A.,Sanftner Laura,Rijnbrand Rene,Abrams Marc,Brown Bob D.
Reference78 articles.
1. Givosiran for acute intermittent porphyria;Balwani;N. Engl. J. Med.,2020
2. Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria;Balwani;N. Engl. J. Med.,2020
3. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis;Adams;N. Engl. J. Med.,2018
4. Nedosiran, a candidate siRNA drug for the treatment of primary hyperoxaluria: Design, development, and clinical studies;Liu;ACS Pharmacol. Transl. Sci.,2022
5. PHYOX2: A pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2;Baum;Kidney Int.,2023